Cystic Fibrosis
Is No Way to Live
- CF is a genetic disease: death from lung failure is late 20’s (average)
- Quality of life is poor, treatment burden high. Lung transplants common
Solution:
Nanoparticle Gene Therapy
STEP 1
Working CF gene formulated with HK polymer to form a nanoparticle
STEP 2
Booster rocket
(PEG-ylation) added to nanoparticle fired (inhaled) at the lung
(PEG-ylation) added to nanoparticle fired (inhaled) at the lung
STEP 3
Booster rocket falls away and the HK polymer transfects the CF gene to the cell
STEP 4
Entire Rocket is <100nm to get through the 140nm pores in thick CF mucus
Delivery, Delivery & Delivery
Strong Transfection Data:
Flow Cytometry
GREEN FLUORESCENT PROTEIN ACTIVITY: 72 HOURS
Up to 48% of all cells transfected and 32 times better than control (DNA only).
Directors
Dr Noreen Henig
- CMO at Breath Theraputics
- Special Advisor, CMO and Chief Development officer at Pro QR
- Senior Director of Global Respiratory at Gilead Sciences, Inc.
- Many years of experience as a Director of Adult Cystic Fibrosis Care Centers
Daniel E. Levy, PHD
- CEO of DEL BioPharma LLC
- Director of Synthetic Chemistry at Intradigm - Corporation pursuing nanoparticle delivery vehicles for siRNA therapeutics.
- Glycomed Inc., COR Therapeutics, Scios, Inc.
Mr John Bulicek
- 25 years experience in investment banking in New York
- Senior leadership positions within key Global Investment Banks including UBS, BNP Paribas, Commerzbank, and Canaccord Genuity
- Owner corporate advisory firm Bulicek and Co
Mr Andrew Venables
- 25+ years experience in law, finance and economics, including 10 years as a Partner of a leading corporate law firm. Listing CFO in oil and gas.
- Experienced in financing gene therapy strategies for treating cystic fibrosis
- CF Dad with extensive connections in the CF community
- avenables@loxegen.net
Scientific Advisory Board: Four World leading CF Professors from Canada, the USA and Israel.